Key result
T2DM and metabolic syndrome in COPD are linked to higher mortality and cardiovascular risk.
Why the study?
Systemic inflammation and hyperglycemia contribute to increased cardiovascular risk in patients with chronic obstructive pulmonary disease and metabolic syndrome, but detailed understanding of their impact on long-term outcomes is needed.
Answers are grounded in this paper and cite their sources.
Metabolic syndrome and hyperglycemia significantly increase cardiovascular risk in patients with COPD through mechanisms involving systemic inflammation, oxidative stress, and endothelial dysfunction.
Chronic obstructive pulmonary disease is a cause of morbidity and mortality worldwide. The presence of infl ammatory markers in circulation, sputum, and broncho-alveolar fl uid suggest systemic infl ammation is one of the potential mechanisms responsible for both chronic obstructive pulmonary disease and metabolic syndrome. Circulating markers of infl ammation, on the other hand, are those that have been found to predict future cardiovascular events as well. One of the main causes of increased cardiovascular risk in patients with chronic obstructive pulmonary disease and metabolic syndrome is hyperglycemia. It induces oxidative stress and subsequently micro- and macrovascular complications. This review describes in details the various components of metabolic syndrome and its impact on long outcomes in chronic obstructive pulmonary disease and cardiovascular pathology.
No takes yet. Share an insight, caveat, or question.
Николаева et al. (2023) conducted a review in Chronic obstructive pulmonary disease and metabolic syndrome. Metabolic syndrome was evaluated. The presence of type 2 diabetes mellitus and metabolic syndrome in patients with chronic obstructive pulmonary disease is associated with increased mortality, impaired lung function, and increased cardiovascular risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: